JP2020063241A5 - - Google Patents

Download PDF

Info

Publication number
JP2020063241A5
JP2020063241A5 JP2019185670A JP2019185670A JP2020063241A5 JP 2020063241 A5 JP2020063241 A5 JP 2020063241A5 JP 2019185670 A JP2019185670 A JP 2019185670A JP 2019185670 A JP2019185670 A JP 2019185670A JP 2020063241 A5 JP2020063241 A5 JP 2020063241A5
Authority
JP
Japan
Prior art keywords
conjugate
linker
tate
targeting moiety
conjugate according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019185670A
Other languages
English (en)
Japanese (ja)
Other versions
JP6932389B2 (ja
JP2020063241A (ja
Filing date
Publication date
Priority claimed from JP2017500064A external-priority patent/JP6602834B2/ja
Application filed filed Critical
Publication of JP2020063241A publication Critical patent/JP2020063241A/ja
Publication of JP2020063241A5 publication Critical patent/JP2020063241A5/ja
Priority to JP2021131359A priority Critical patent/JP2021175757A/ja
Application granted granted Critical
Publication of JP6932389B2 publication Critical patent/JP6932389B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019185670A 2014-06-30 2019-10-09 標的化コンジュゲートならびにその粒子及び製剤 Expired - Fee Related JP6932389B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021131359A JP2021175757A (ja) 2014-06-30 2021-08-11 標的化コンジュゲートならびにその粒子及び製剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462019001P 2014-06-30 2014-06-30
US62/019,001 2014-06-30
US201462077487P 2014-11-10 2014-11-10
US62/077,487 2014-11-10
US201562150413P 2015-04-21 2015-04-21
US62/150,413 2015-04-21
JP2017500064A JP6602834B2 (ja) 2014-06-30 2015-06-30 標的化コンジュゲートならびにその粒子及び製剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017500064A Division JP6602834B2 (ja) 2014-06-30 2015-06-30 標的化コンジュゲートならびにその粒子及び製剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021131359A Division JP2021175757A (ja) 2014-06-30 2021-08-11 標的化コンジュゲートならびにその粒子及び製剤

Publications (3)

Publication Number Publication Date
JP2020063241A JP2020063241A (ja) 2020-04-23
JP2020063241A5 true JP2020063241A5 (https=) 2020-06-11
JP6932389B2 JP6932389B2 (ja) 2021-09-08

Family

ID=55020088

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017500064A Expired - Fee Related JP6602834B2 (ja) 2014-06-30 2015-06-30 標的化コンジュゲートならびにその粒子及び製剤
JP2019185670A Expired - Fee Related JP6932389B2 (ja) 2014-06-30 2019-10-09 標的化コンジュゲートならびにその粒子及び製剤
JP2021131359A Pending JP2021175757A (ja) 2014-06-30 2021-08-11 標的化コンジュゲートならびにその粒子及び製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017500064A Expired - Fee Related JP6602834B2 (ja) 2014-06-30 2015-06-30 標的化コンジュゲートならびにその粒子及び製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021131359A Pending JP2021175757A (ja) 2014-06-30 2021-08-11 標的化コンジュゲートならびにその粒子及び製剤

Country Status (15)

Country Link
US (4) US9750818B2 (https=)
EP (1) EP3160518A4 (https=)
JP (3) JP6602834B2 (https=)
KR (2) KR102062025B1 (https=)
CN (2) CN106573077B (https=)
AU (2) AU2015284236B2 (https=)
BR (1) BR212016030926U2 (https=)
CA (1) CA2953371C (https=)
IL (1) IL249647B (https=)
MX (1) MX379365B (https=)
PH (1) PH12017500023A1 (https=)
RU (1) RU2695220C2 (https=)
SG (1) SG11201610880RA (https=)
WO (1) WO2016004048A2 (https=)
ZA (1) ZA201608432B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190015350A1 (en) 2013-02-05 2019-01-17 Anp Technologies, Inc. Nanoparticles Containing a Taxane and their Use
US9533054B2 (en) * 2013-03-11 2017-01-03 Shanghai Jiao Tong University Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof
MX379365B (es) 2014-06-30 2025-03-11 Tarveda Therapeutics Inc Conjugados y partículas direccionados y formulaciones de estos.
WO2017003940A1 (en) * 2015-06-30 2017-01-05 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
BR112018000217A2 (pt) * 2015-07-15 2018-09-04 Celator Pharmaceuticals Inc sistemas de distribuição de nanopartículas aperfeiçoados
US11160871B2 (en) 2015-10-28 2021-11-02 Tarveda Therapeutics, Inc. SSTR-targeted conjugates and particles and formulations thereof
RU2736590C2 (ru) 2016-02-16 2020-11-18 Стронгбридж Даблин Лимитед Велдореотид, обладающий плохой растворимостью в физиологических условиях, для применения при лечении акромегалии, акромегалии со злокачественным новообразованием, экспрессирующих sst-r5 опухолей, диабета 2 типа, гипергликемии и опухолей, связанных с гормонами
WO2017161096A1 (en) * 2016-03-16 2017-09-21 Tarveda Therapeutics, Inc. Antibody mimic conjugates and particles
EP3442592A4 (en) * 2016-04-13 2019-11-27 Tarveda Therapeutics, Inc. NEUROTENSIN RECEPTOR BINDING CONJUGATES AND FORMULATIONS THEREOF
WO2017210246A2 (en) * 2016-05-31 2017-12-07 Tarveda Therapeutics, Inc. Penicillamine conjugates and particles and formulations thereof
WO2018041942A1 (en) 2016-08-31 2018-03-08 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh New polymer linked multimers of guanosine-3', 5'-cyclic monophosphates
CN109890423A (zh) * 2016-10-28 2019-06-14 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂
WO2018222987A1 (en) * 2017-06-01 2018-12-06 Tarveda Therapeutics, Inc. Targeted constructs
CA3069159A1 (en) * 2017-07-11 2019-01-17 Sustained Nano Systems Llc Hypercompressed pharmaceutical formulations
CN107422021B (zh) * 2017-07-14 2019-11-19 北京朗阅科技有限公司 琼脂糖胶囊及其制备方法与应用
CA3073604A1 (en) * 2017-08-25 2019-02-28 Nal Pharmaceutical Group Limited Compositions and methods of delivery of pharmacological agents
CA3078776A1 (en) * 2017-10-27 2019-05-02 Tarveda Therapeutics, Inc. Sstr-targeted conjugates and formulations thereof
WO2019118830A1 (en) * 2017-12-14 2019-06-20 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
EP3801506A4 (en) * 2018-06-01 2022-08-10 Tva (Abc), Llc POLYTHERAPY
CN109124096B (zh) * 2018-08-23 2021-08-06 广州百隆威尔精密五金制品有限公司 一种升降橱柜
BR112021005320A2 (pt) * 2018-12-17 2021-06-15 Remegen Co., Ltd. ligante para conjugados de anticorpo-fármaco e seu uso
WO2020191011A1 (en) * 2019-03-18 2020-09-24 The Trustees Of Columbia University In The City Of New York Non-hydrolyzable, non-cleavable, stable linkers for precision therapeutics and uses thereof
CN109848440A (zh) * 2019-04-10 2019-06-07 燕山大学 一种钯纳米立方体的制备方法
CA3143373A1 (en) * 2019-06-25 2020-12-30 Tarveda Therapeutics, Inc. Sstr-targeted conjugates and formulations thereof
CN119236187A (zh) 2020-02-21 2025-01-03 吉益医疗公司 聚合物包封的药物颗粒
CN112250647A (zh) * 2020-06-30 2021-01-22 浙江大学 紫杉烷类药物前体、制备方法和应用
US11571481B2 (en) 2020-12-21 2023-02-07 Cornell University Peptide-linked drug delivery system
WO2022174171A1 (en) 2021-02-15 2022-08-18 Anp Technologies, Inc. Pharmaceutical composition containing taxane nanoaggregates and use thereof
TW202302073A (zh) * 2021-03-18 2023-01-16 予宇生技股份有限公司 包含帶電脂質的脂質製劑的組合物及製備方法
JP2024512659A (ja) * 2021-04-01 2024-03-19 アール．ピー．シェーラー テクノロジーズ，エルエルシー 医薬製剤におけるアニオン性キレート剤としてのリン脂質
IT202100014330A1 (it) * 2021-06-01 2022-12-01 The Ubeauty Com Llc Prodotto per la cura della pelle e procedimento per la sua realizzazione.
CN118005545B (zh) * 2024-01-04 2025-02-18 兰州大学 小分子抗菌肽模拟物及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5843903A (en) * 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
AT405906B (de) 1997-03-14 1999-12-27 Irene Dr Virgolini Radiomarkierte somatostatin rezeptor-liganden zur diagnose und therapie
US6358491B1 (en) * 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
WO2001032218A1 (en) * 1999-11-01 2001-05-10 University Technology Corporation Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
DE10006572A1 (de) * 2000-02-14 2001-08-23 Deutsches Krebsforsch Oligonucleotid-Konjugate
FR2824563B1 (fr) * 2001-05-10 2004-12-03 Bio Merieux Particules composites, conjugues derives, procede de preparation et applications
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US8877901B2 (en) * 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
EP1531846A4 (en) 2002-02-27 2006-04-19 Us Gov Health & Human Serv Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
US7771727B2 (en) 2002-03-01 2010-08-10 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
ES2377318T3 (es) * 2002-09-06 2012-03-26 Cerulean Pharma Inc. Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
TWI260228B (en) * 2002-12-31 2006-08-21 Ind Tech Res Inst Delivery carrier of presenting cell of somatostatin receptor
CA2523605A1 (en) 2003-03-10 2004-09-23 Charles W. Spangler Targeted agents for both photodiagnosis and photodynamic therapy
CN101791409A (zh) * 2003-04-22 2010-08-04 研究及应用科学协会股份有限公司 肽载体
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
MXPA05011811A (es) * 2003-05-20 2006-02-17 Immunogen Inc Agentes citotoxicos mejorados que comprenden nuevos maitansinoides.
JP4318985B2 (ja) * 2003-08-21 2009-08-26 日本メジフィジックス株式会社 ソマトスタチンアナログ誘導体およびその利用
ES2503719T3 (es) * 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
CA3000520C (en) 2005-08-24 2023-04-04 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
EP2354163A3 (en) 2005-09-26 2013-04-24 Medarex, Inc. Conjugates of duocarmycin and anti-CD70 or anti-PSMA antibodies
EP1864682A1 (en) * 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
US10925977B2 (en) * 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
TW200831129A (en) * 2006-10-06 2008-08-01 Amgen Inc Stable formulations
DK2644194T3 (en) 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
JP2011519894A (ja) * 2008-05-06 2011-07-14 グラクソ グループ リミテッド 生物活性薬の封入
KR101324804B1 (ko) * 2008-05-13 2013-11-01 아이알엠 엘엘씨 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
FR2945211A1 (fr) * 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
DK3223013T3 (en) * 2009-07-02 2019-04-15 Sloan Kettering Inst Cancer Res FLUORESCING SILICA-BASED NANOPARTICLES
EP2518086A1 (en) 2009-12-25 2012-10-31 Riken Radiolabeled compound directable in vivo to target tissue and use thereof
MX2012012383A (es) * 2010-04-30 2012-11-30 Sanwa Kagaku Kenkyusho Co Peptido para mejorar la bioestabilidad de una sustancia bioactica y sustancia bioactiva que tiene bioestabilidad mejorada.
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CA2810838C (en) * 2010-09-08 2021-07-06 The Board Of Regents Of The University Of Texas System Somatostatin receptor-based cancer therapy
AU2012223364A1 (en) * 2011-03-01 2013-09-19 Ge Healthcare Limited Radiolabelled Octreotate analogues as PET tracers
WO2012138911A2 (en) * 2011-04-05 2012-10-11 The Administrators Of The Tulane Educational Fund Conjugates of anti-hiv drugs and somatostatin analogs
WO2012145112A2 (en) 2011-04-18 2012-10-26 Immunogen, Inc. Novel maytansinoid derivatives with sulfoxide linker
CA2836338C (en) * 2011-05-16 2022-05-03 Koninklijke Philips N.V. Tetrazine derivatives used in bio-orthogonal drug activation
JP6209159B2 (ja) 2011-06-21 2017-10-04 イミュノジェン・インコーポレーテッド ペプチドリンカーを有する新規メイタンシノイド誘導体およびその結合体
JP6355563B2 (ja) * 2012-02-27 2018-07-11 アムニクス オペレーティング インコーポレイテッド Ｘｔｅｎ共役組成物およびそれを製造する方法
EP2895146A1 (en) * 2012-09-17 2015-07-22 BIND Therapeutics, Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
EP3566750A3 (en) 2013-02-28 2020-04-08 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
CN105814083A (zh) 2013-10-15 2016-07-27 加州生物医学研究所 嵌合抗原受体t细胞开关和其用途
MX379365B (es) * 2014-06-30 2025-03-11 Tarveda Therapeutics Inc Conjugados y partículas direccionados y formulaciones de estos.

Similar Documents

Publication Publication Date Title
JP2020063241A5 (https=)
JP6092867B2 (ja) 担体連結しているトレプロスチニルプロドラッグ
CN108164474B (zh) 作为免疫调节剂的1,2,4-二唑衍生物
US9096642B2 (en) Therapeutic compounds for immunomodulation
JP7483776B2 (ja) 放出制御ｐｔｈ化合物の漸増用量設定
JP2020514300A5 (https=)
RU2548905C2 (ru) Терапевтические пептиды
CN103874480A (zh) 前列环素的缓释组合物
EP1480657A1 (en) Polymers for delivering peptides and small molecules i in vivo /i
JPWO1999061061A1 (ja) 薬物複合体
JP2010521485A5 (https=)
RU2007131504A (ru) Пептиды, обладающие агонистической активностью в отношении рецептора нейропептида-2-(y2r)
WO2011042453A1 (en) Subcutaneous paliperidone composition
US11077082B2 (en) Composition and method for dual targeting in treatment of neuroendocrine tumors
US20170014524A1 (en) Auristatin-antibody conjugates and uses thereof
US8518891B2 (en) Chemotherapeutic conjugates and methods of use
KR101828613B1 (ko) 올리고머-칼슘 모방체 컨쥬게이트 및 관련 화합물
SK150196A3 (en) Peptides with immunomodulatory effects, pharmaceutical formulations containing them and their use
WO2020205996A2 (en) Locally acting toll-like receptor 7 (tlr7) and/or tlr8 agonist immunotherapy compounds and their uses
JP7339285B2 (ja) Ｔｌｒ７ペプチドコンジュゲート
EP1372733B1 (en) Pharmaceutical compositions of active polypeptides for enhanced pharmacological activity through oral and parenteral administration
US20220362278A1 (en) Renal targeting-type drug delivery carrier having excellent biodegrability
US11351137B2 (en) Composition and method for dual targeting in treatment of neuroendocrine tumors
KR20170091610A (ko) 신규 peg 유도체
RU2789198C2 (ru) Композиция и способ двойного нацеливания при лечении нейроэндокринных опухолей